Covid19 Clinical Trial - Risk Identification of Long-term Complications

Status Enrolling by invitation

Clinical Trial Summary

The investigators retrospectively analyze the clinical characteristics of severe COVID-19 in our hospital, and then establish a prediction model for long-term complications in patients with severe COVID-19, and strengthen follow-up to improve the prognosis of patients.

Clinical Trial Description

At present, there is a lack of prediction models for the long-term complications of severe COVID-19. Therefore, the investigators used the hospital big data platform to retrospectively analyze the clinical characteristics of severe COVID-19 in our hospital, and conducted cohort follow-up of the changes in lung function including FEV1, FVC，FEV1% and DLCO, etc and and high-resolution CT of patients after discharge. COX model and other statistical methods were used to establish a prediction model for long-term complications of severe COVID-19, and early identification and intervention, strengthen follow-up, and improve the prognosis of patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06235866
Study type	Observational
Source	Wuhan Central Hospital
Contact
Status	Enrolling by invitation
Phase
Start date	February 1, 2023
Completion date	November 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05175833` - Oral Probiotics and Secondary Bacterial Pneumonia in Severe COVID-19	Phase 2
Recruiting	`NCT05256511` - COVID-19 and VA-LRTI: Second Versus First Wave of the Pandemic
Completed	`NCT04866082` - Corticosteroids in Severe COVID-19 (ASAP-ESICM/ESAIC Study)
Active, not recruiting	`NCT04918901` - Comparative Analysis of Clinical Parameters and Radiographic Changes of Severe COVID-19
Recruiting	`NCT05233605` - Impact of Post-ARDS Covid-19 Sedation on Persistent Neuroinflammation
Not yet recruiting	`NCT04613986` - Therapeutic Plasma Exchange as an Adjunctive Strategy to Treat Coagulopathy and Inflammation in Severe Covid-19	N/A
Recruiting	`NCT05447013` - Generation of SARS-CoV-2-specific T Lymphocytes From Recovered Donors and Administration to High-risk COVID-19 Patients	Phase 1/Phase 2
Completed	`NCT04733833` - A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19	Phase 2
Recruiting	`NCT04712344` - Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO)	Phase 2
Terminated	`NCT04713176` - Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients	Phase 3
Recruiting	`NCT04648410` - Corticosteroids in Severe COVID-19(ASAP-C Study)
Recruiting	`NCT05254990` - Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia	Phase 3
Completed	`NCT05596617` - Safety and Efficacy of Medications COVID-19	N/A